Dr. Wang works on biomarker identification using multiparametric magnetic resonance imaging and homo- and hetero-nuclear spectroscopy techniques for pediatric disease research including tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, Gaucher’s, and Canavan’s diseases.
Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.
Dr. Roberts investigates brain-wave scanning with magnetoencephalography (MEG) and works to identify biomarkers for neuropsychiatric disorders like autism. Those biomarkers are for diagnosis, prognosis, stratification, and response monitoring as well as substrate identification for targeted therapy. Putting the "bio" into biomarkers is a major emphasis of Dr. Roberts' research, for which he uses advanced diffusion magnetic resonance imaging (MRI) and edited spectroscopy.
Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. Nadir Yehya is interested in all aspects of mechanical ventilation and respiratory failure in children, including pre-clinical models, ventilator-induced lung injury, and acute respiratory distress syndrome.
Dr. Lynch maintains a dynamic program that involves clinical, translational, and basic science research efforts focused on the rare disease Friedreich ataxia.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. Weiss' research focuses on epidemiology of pediatric sepsis and mitochondrial dysfunction in sepsis-associated organ injury. The driving hypothesis for his research is that alterations in mitochondrial bioenergetics contribute to organ injury and immune dysregulation in a subset of children with sepsis.
Using translational approaches that encompass genomic studies, biomarker development, disease modeling, natural history studies, and clinical trials, Dr. Vanderver seeks to improve the quality of life and lifespan of individuals living with leukodystrophies or heritable disorder of myelin. She leads the Leukodystrophy Center of Excellence at Children's Hospital of Philadelphia.
Dr. Ghanem investigates the impact of transcriptional gene expression controls and mRNA processing upon the severity and progression of pediatric inflammatory bowel disease.
